The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
Establishment of 220 smart classrooms across Uttar Pradesh, Uttarakhand, and Himachal Pradesh
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
The National One Health Mission will help India to achieve integrated disease control and pandemic preparedness
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
Project achieves 30% reduction in hospital acquired infections and 24% reduction in the incidence of multi-drug resistant organisms
The restructuring aims to create synergies across the business and strengthen capital structure
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Aarti Drugs has reported total income of Rs. 607.61 crores during the period ended December 31, 2023
Subscribe To Our Newsletter & Stay Updated
